top of page
![](https://static.wixstatic.com/media/11062b_61dbd21e9e0041c4b08c1b7fdee0c36f~mv2_d_6000_4000_s_4_2.jpg/v1/fill/w_1920,h_1280,al_c,q_90,usm_0.66_1.00_0.01,enc_avif,quality_auto/11062b_61dbd21e9e0041c4b08c1b7fdee0c36f~mv2_d_6000_4000_s_4_2.jpg)
Aducanumab and Persons with Down Syndrome: What Do We Do Now? (Statement)
Resource document
NTG issued statement on use of Aduhelm by persons with Down syndrome. This statement, the result of a collaborative effort coordinated by the NTG Aduhelm and Down Syndrome Medical Advisory Group, was led by Seth M. Keller, MD, Co-President of the National Task Group on Intellectual Disabilities and Dementia Practices.
bottom of page